TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$3.05 +0.09 (+3.04%) As of 03:26 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Medexus Pharmaceuticals Stock (TSE:MDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDP alerts:Sign Up Key Stats Today's RangeC$3.00▼C$3.0850-Day RangeC$2.50▼C$3.4052-Week RangeC$1.71▼C$5.56Volume33,250 shsAverage Volume79,119 shsMarket CapitalizationC$68.28 millionP/E Ratio14.59Dividend YieldN/APrice TargetC$5.49Consensus RatingBuy Company Overview Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action. Read More Medexus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMDP MarketRank™: Medexus Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMedexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedexus Pharmaceuticals has received no research coverage in the past 90 days.Read more about Medexus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Medexus Pharmaceuticals is 14.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Medexus Pharmaceuticals is 14.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.Price to Book Value per Share RatioMedexus Pharmaceuticals has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedexus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMedexus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDP. News and Social Media0.6 / 5News SentimentN/A News SentimentMedexus Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medexus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.Read more about Medexus Pharmaceuticals' insider trading history. Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDP Stock News HeadlinesEquities Analysts Issue Forecasts for TSE:MDP Q4 EarningsJuly 1, 2025 | americanbankingnews.comMedexus Pharmaceuticals Inc (TSX:MDP) Q4 2025: Everything You Need To Know Ahead Of EarningsJune 27, 2025 | finance.yahoo.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 10 at 2:00 AM | Porter & Company (Ad)Medexus Pharmaceuticals Inc (TSX:MDP) Q4 2025 Earnings Report Preview: What To Look ForJune 26, 2025 | finance.yahoo.comShould We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?April 18, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDPJanuary 29, 2025 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - MDPJanuary 29, 2025 | ca.finance.yahoo.comDespite the downward trend in earnings at Medexus Pharmaceuticals (TSE:MDP) the stock spikes 16%, bringing one-year gains to 48%December 25, 2024 | finance.yahoo.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$3.46 at the start of the year. Since then, MDP stock has decreased by 11.8% and is now trading at C$3.05. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Price Target for Medexus PharmaceuticalsC$5.49 High Price TargetC$8.25 Low Price TargetC$3.45 Potential Upside/Downside+85.4%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)C$0.21 Trailing P/E Ratio14.15 Forward P/E Ratio18.12 P/E GrowthN/ANet IncomeC$3.26 million Net Margins3.25% Pretax MarginN/A Return on Equity11.07% Return on Assets4.89% Debt Debt-to-Equity Ratio120.58 Current Ratio1.01 Quick RatioN/A Sales & Book Value Annual SalesC$100.25 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.35 per share Price / Book2.19Miscellaneous Outstanding Shares22,388,156Free FloatN/AMarket CapC$66.27 million OptionableNot Optionable Beta1.96 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (TSE:MDP) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.